Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis

Journal of the American Society of Nephrology

Volumn 9, Issue 6, 1998, Pages 1104-1108

  Julian, Bruce A ^a   Brantley, Roman R ^a   Barker, Catherine V ^a   Stopka, Tomas ^a   Gaston, Robert S ^a   Curtis, John J ^a   Lee, Jeannette Y ^a   Prchal, Josef T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ERYTHROPOIETIN; LOSARTAN; RENIN;

ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTOSIS; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HUMAN; KIDNEY TRANSPLANTATION; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031778819     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Perazella MA, Bia MJ: Posttransplant erythrocytosis: Case report and review of the newer treatment modalities. J Am Soc Nephrol 3: 1653-1659, 1993
2. Nellans R, Otis P, Martin DC: Polycythemia following renal transplantation. Urology 6: 158-163, 1975
3. Gaston RS, Julian BA, Curtis JJ: Posttransplant erythrocytosis: An enigma revisited. Am J Kidney Dis 24: 1-11, 1994
4. Qunibi WY, Barri Y, Devol E, Al-Furayh O, Sheth K, Taher S: Factors predictive of post-transplant erythrocytosis. Kidney Int 40: 1153-1159, 1990
5. Glicklich D, Tellis VA, Matas AJ, Mallis M, Quinn T, Soberman R, Veith FJ: No association between post-transplant erythrocytosis, thromboembolic events, and cyclosporine therapy. Transplant Proc 21: 2141-2142, 1989
6. Innes A, Pal CR, Dennis MJ, Ryan JJ, Morgan AG, Burden RP: Post-transplant erythrocytosis and immunosuppression with cyclosporine: A case-control study. Nephrol Dial Transplant 6: 588-591, 1991
7. Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM: Postrenal transplant erythrocytosis: A review of 53 patients. Kidney Int 23: 731-737, 1983
8. Gruber SA, Simmons RL, Najarian JS, Vercellotti G, Ascher NL, Dunn DL, Payne WD, Sutherland DER, Fryd DS: Posttransplant erythrocytosis and the risk of thromboembolic complications: Correlation from a prospective randomized study of cyclosporine versus azathioprine-antilymphocyte globulin. Clin Transplant 2: 60-66, 1988
9. Gaston RS, Julian BA, Barker CV, Diethelm AG, Curtis JJ: Enalapril: Safe and effective therapy for posttransplant erythrocytosis. Transplant Proc 25: 1029-1031, 1993
10. Islam MS, Bourbigot B, Codet JP, Songy B, Fournier G, Cledes J: Captopril induces correction of postrenal transplant erythremia. Transplant Int 3: 222-225, 1990
11. Conlon P, Farrell J, Donohoe J, Carmody M, Walshe JJ: The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation 56: 217-219, 1993
12. Ramos EL, Balagtas R: Post-transplant erythrocytosis. J Nephrol 5: 9-13, 1993
13. Danovitch GM, Jamgotchian NJ, Eggena PH, Wellington P, Barrett JD, Wilkinson A, Lee DBN: Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Transplantation 60: 132-137, 1995
14. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ: Enalapril treatment of posttransplant erythrocytosis: Efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 26: 495-500, 1995
15. Gossmann J, Thurmann P, Bachmann T, Weller S, Kachel H-G, Schoeppe W, Scheuermann E-H: Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50: 973-978, 1996
16. Haber E, Koerner T, Page LB, Kliman B, Prunode A: Application of a radioimmunoassay for angiotensin I to the physiologic measurements of PRA in normal human subjects: Renin activity by angiotensin I radioimmunoassay. J Clin Endocrinol Metab 24: 1349-1355, 1969
17. Rivalan J, Morin MP, Joyeux V, Le Pogamp P: Posttransplant erythrocytosis treatment with losartan [Abstract]. J Am Soc Nephrol 7: 1939, 1996
18. Ducloux D, Bresson-Vautrin C, Chalopin JM: Effects of angiotensin-receptor antagonists on erythrocytosis after renal transplantation [Letter]. Nephrol Dial Transplant 11: 1668, 1996
19. Midtvedt K, Stokke ES, Hartmann A: Successful long-term treatment of post-transplant erythrocytosis with losartan [Letter]. Nephrol Dial Transplant 11: 2495-2497, 1996
20. Conlon PJ, Smith SR, Butterly DW, Brennan DC: Losartan in post-transplant erythrocytosis [Letter]. Nephrol Dial Transplant 11: 2524-2525, 1996
21. Eustace JA, Mellote GJ, Keogh JAB: Treatment of post-transplant erythrocytosis by angiotensin II type I receptor antagonists [Letter]. Nephrol Dial Transplant 11: 2373-2374, 1996
22. Thevenod F, Radtke HW, Grutzmacher P, Vincent E, Koch K-M, Schoeppe W, Fassbinder W: Deficient feedback regulation of erythropoiesis in kidney transplant patients with polycythemia. Kidney Int 24: 227-232, 1983
23. Dagher FJ, Ramos E, Erslev AJ, Alongi SV, Karmi SA. Caro J: Are the native kidneys responsible for erythrocytosis in renal allorecipients? Transplantation 28: 496-498, 1979
24. Sauron C, Berthoux P, Berthoux F, Alamartine E, Diab N, Groyet C, Hacini J: New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc 25: 1032-1033, 1993
25. Garvin PJ, Reese JC, Lindsey L, Aridge DL, Domoto DT, Ballal S: Bilateral nephrectomy for posttransplant erythrocytosis: Indications and results. Clin Transplant 5: 313-317, 1991
26. Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R: Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 323: 86-90, 1990
27. Fried W, Barone-Varelas J, Barone T, Anagnostou A: Effect of angiotensin infusion on extrarenal erythropoietin production. J Lab Clin Med 99: 520-525, 1982
28. Gould AB, Goodman S, DeWolf R, Onesti G, Schwartz C: Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 96: 523-534, 1980
29. Pidgeon GB, Bailey RR, Lynn KL, Richards AM, Nichols MG: Effect of angiotensin II infusion on plasma erythropoietin in healthy volunteers. 13th International Congress of Nephrology Program Book, Madrid, Spain, 1995, p 502
30. Pratt MC, Lewis-Barned NJ, Walker RJ, Bailey RR. Shand BI, Livesey J: Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34: 363-365, 1992
31. Aeberhard J-M, Schneider P-A, Vallotton MB, Kurtz A, Leski M: Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 50: 613-616, 1990
32. Mrug M, Stopka T, Julian RA, Prchal JF, Prchal JT: Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100: 2310-2314, 1997
33. 1 receptor. Nature 375: 247-250, 1995
34. Regitz-Zagrosek V, Auch-Schwelk W, Hess B, Klein U, Duske E, Steffen C, Hildebrandt AG, Fleck E: Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporine A, angiotensin-converting enzyme inhibitors and AT1 antagonists. J Cardiovasc Pharmacol 26: 66-72, 1995
35. Lenfant M. Wdzieczak-Bakala J, Guittet E, Prome J-C, Sotty D, Frindel E: Inhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure. Biochemistry 86: 779-782, 1989
36. Azizi M, Rousseau A, Ezan E, Guyene T-T, Michelet S, Grognet J-M, Lenfant M, Corvol P, Menard J: Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97: 839-844, 1996